M&A - CITIUS ONCOLOGY, INC.

Form Type: 10-K/A

Filing Date: 2025-01-27

Corporate Action: Acquisition

Type: Update

Accession Number: 000121390025007012

Filing Summary: Citius Oncology, Inc. filed this Form 10-K/A as an amendment to their Annual Report for the fiscal year ended September 30, 2024. The amendment provides detailed information required by SEC Items 10, 11, 12, 13, and 14, which were previously omitted in the original filing dated December 27, 2024. The report discusses the company's corporate governance structure, executive compensation, security ownership, related transactions, and accountant fees. Notably, the company, originally formed as TenX Keane Acquisition Corp. and reincorporated in Delaware, completed the acquisition of its subsidiary Citius Oncology Sub, Inc. on August 12, 2024. This filing also includes certifications from the principal executive and financial officers in compliance with the Sarbanes-Oxley Act. No financial statements were included, and the report does not reflect events that occurred after the original filing date. The document emphasizes the company's compliance with SEC regulations and transparency in management practices.

Document Link: View Document

Form Type: 10-K

Filing Date: 2024-12-27

Corporate Action: Merger

Type: New

Accession Number: 000121390024113150

Filing Summary: Citius Oncology, Inc. is a biopharmaceutical company focused on developing targeted oncology therapies, particularly LYMPHIR, which received FDA approval in August 2024 for treating patients with persistent or recurrent CTCL. The report highlights the company's business development, emphasizing its strategy to achieve a market-leading position by advancing innovative therapies. Notably, it discusses the merger with TenX Keane Acquisition that was completed on August 12, 2024, with Citius Pharma owning approximately 92.3% of the outstanding shares post-merger. The company also faces operational challenges, such as securing substantial funding, the commercialization of LYMPHIR, and navigating a competitive market landscape.

Document Link: View Document